We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+50.85%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$1.1B
AUM Growth
+$345M
Cap. Flow
+$47.4M
Cap. Flow %
4.29%
Top 10 Hldgs %
64.76%
Holding
67
New
13
Increased
15
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$29.8M
2
IMMX icon
Immix Biopharma
IMMX
+$21.8M
3
MGTX icon
MeiraGTx Holdings
MGTX
+$14.2M
4
GLUE icon
Monte Rosa Therapeutics
GLUE
+$14.1M
5
VSTM icon
Verastem
VSTM
+$8.71M

Top Sells

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$19.5M
2
HROW icon
Harrow
HROW
+$16.1M
3
SNWV
SANUWAVE Health Inc
SNWV
+$10.5M
4
JBIO
Jade Biosciences
JBIO
+$5.89M
5
LQDA icon
Liquidia Corp
LQDA
+$5.23M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
26
Cabaletta Bio
CABA
$529M
$12M 1.09%
3,863,800
+2,483,800
+180% +$8.17M
QTTB icon
27
Q32 Bio
QTTB
$447M
$11.9M 1.07%
931,000
-325,228
-26% -$2.72M
ANNX icon
28
Annexon
ANNX
$942M
$9.79M 0.89%
1,714,451
-617,310
-26% -$3.41M
VSTM icon
29
Verastem
VSTM
$654M
$6.88M 0.62%
+1,800,000
New +$8.71M
ZNTL icon
30
Zentalis Pharmaceuticals
ZNTL
$360M
$6.85M 0.62%
1,412,656
– –
RLMD icon
31
Relmada Therapeutics
RLMD
$462M
$6.47M 0.59%
935,000
– –
OCUL icon
32
Ocular Therapeutix
OCUL
$2.28B
$5.89M 0.53%
600,000
– –
TRVI icon
33
Trevi Therapeutics
TRVI
$2.39B
$5.78M 0.52%
310,000
-35,100
-10% -$510K
BBOT
34
BridgeBio Oncology
BBOT
$701M
$5.33M 0.48%
700,000
+646,718
+1,214% +$5.4M
LYEL icon
35
Lyell Immunopharma
LYEL
$356M
$4.83M 0.44%
344,025
+264,928
+335% +$4.79M
IRD
36
Opus Genetics
IRD
$307M
$4.62M 0.42%
1,125,000
+5,000
+0.4% +$23.3K
FDMT icon
37
4D Molecular Therapeutics
FDMT
$810M
$4.45M 0.4%
334,437
+222,146
+198% +$2.16M
NTLA icon
38
Intellia Therapeutics
NTLA
$1.8B
$4.23M 0.38%
250,000
+5,000
+2% +$70K
VYGR icon
39
Voyager Therapeutics
VYGR
$218M
$4.15M 0.38%
1,185,000
+35,000
+3% +$133K
BDSX icon
40
Biodesix
BDSX
$283M
$4.06M 0.37%
180,000
-58,047
-24% -$860K
RCKT icon
41
Rocket Pharmaceuticals
RCKT
$424M
$3.42M 0.31%
1,000,000
+45,000
+5% +$150K
JBIO
42
Jade Biosciences
JBIO
$1.33B
$3.22M 0.29%
145,000
-282,608
-66% -$5.89M
SNWV
43
SANUWAVE Health Inc
SNWV
$40.2M
$3.06M 0.28%
306,140
-675,127
-69% -$10.5M
FBIO icon
44
Fortress Biotech
FBIO
$92.4M
$2.72M 0.25%
890,000
-152,000
-15% -$392K
DERM icon
45
Journey Medical
DERM
$211M
$2.48M 0.22%
350,000
-610,000
-64% -$3.48M
PHAT icon
46
Phathom Pharmaceuticals
PHAT
$743M
$2.01M 0.18%
+185,589
New +$2.12M
INBX icon
47
Inhibrx
INBX
$1.82B
$1.92M 0.17%
+20,291
New +$2.03M
ENTA icon
48
Enanta Pharmaceuticals
ENTA
$396M
$1.82M 0.17%
125,000
– –
COAG
49
Hemab Therapeutics
COAG
$2.09B
$1.75M 0.16%
+47,652
New +$1.31M
TRAX
50
First Tracks Biotherapeutics
TRAX
$1.5B
$1.31M 0.12%
+65,000
New +$1.22M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2026 Portfolio in Review

As of Q2 2026, Opaleye Management held 67 positions worth $1.1B, up 45% from $759M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Opaleye Management deployed $47.4M of net new capital in Q2 2026, opening 13 new positions and adding to 15 existing holdings. Its largest new stake was Immix Biopharma: 2,345,000 shares worth $24.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Harrow, an estimated $16.1M trimmed.

  • Opaleye Management's largest Q2 2026 buy was Immix Biopharma: 2,345,000 shares worth $24.2M.
  • Opaleye Management added most to Disc Medicine in Q2 2026, an estimated $29.8M increase.
  • Opaleye Management's biggest Q2 2026 reduction was Harrow, cutting an estimated $16.1M.
  • Opaleye Management fully exited Perspective Therapeutics in Q2 2026, selling an estimated $19.5M.
  • Opaleye Management's ten largest holdings make up 65% of its $1.1B portfolio in Q2 2026.
  • Opaleye Management opened 13 new positions and closed 9 in Q2 2026.
  • Opaleye Management's portfolio value rose 45% quarter-over-quarter to $1.1B.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.